Clinical trial

The Effect of Fluid Loading With Early Norepinephrine Administration on Stroke Volume Index, Cardiac Index, Lactate, and Arterial Elastance in Pediatric Septic Shock

Name
23-12-2106
Description
The complexity of pediatric septic shock arise from its varied pathophysiology, which includes systemic inflammation, cardiovascular collapse, and multiple organ dysfunction. Current standard treatments, which primarily focusedon fluid resuscitation, had exhibited several problems. Excessive fluid resuscitation has been associated with complications such as fluid overload, which may cause conditions such as pulmonary edema and organ dysfunction, leading to worsened outcomes. This emphasizes the need for alternative therapeutic strategies that can effectively manage hemodynamic instability while minimizing the risks of fluid overload. In adult patients, the early use of vasopressors has been recommended to restore perfusion in patients with septic shock, compared to repeated fluid loading. However, previous research on the use of norepinephrine and the preload status of the pediatric population is still limited. In addition, the use of fluid resuscitation does not always exhibit the desirable response, which is the increase of blood pressure. This is because the blood pressure depends not only on the stroke volume but also the vascular resistance. Consequently, predicting blood pressure elevation after fluid resuscitation remains challenging. Based on previous research, arterial elastance has the potential to predict the increase of blood pressure in response to fluid administration. Thus, this study aimed to investigate the effects of early administration of fluid resuscitation combined with norepinephrine in pediatric septic shock patients and evaluate the useof arterial elastance as a predictor of blood pressure response following fluid resuscitation. Finally, this study will also evaluate the parameters such as stroke volume index, cardiac index, lactate clearance , arterial elastance in pediatric patients with septic shock who were resuscitated using the hemodynamic support guidelines according to the Surviving Sepsis Campaign protocols.
Trial arms
Trial start
2024-03-25
Estimated PCD
2024-05-31
Trial end
2024-05-31
Status
Completed
Phase
Early phase I
Treatment
Ringer's lactate with norepinephrine
NE Group (Fluid loading with early norepinephrine administration group) NE Group will receive ringer lactate bolus 20 ml/kg along with norepinephrine infusion at 0.1 mcg/kg/minute until MAP\>5 percentile. Additional fluid boluses of 10-20 ml/kg will be administered (up to a total of 60 ml/kg) until shock resolution or signs of fluid overload are observed, with or without continued norepinephrine infusion according to the treatment group
Arms:
NE Group (Fluid loading with early norepinephrine administration group)
Ringer's Lactate
Fluid Group will receive ringer lactate bolus 20 ml/ kg only. Additional fluid boluses of 10-20 ml/kg will be administered (up to a total of 60 ml/kg) until shock resolution or signs of fluid overload are observed
Arms:
Fluid Group
Size
42
Primary endpoint
stroke volume index
evaluate one hour after intervention
cardiac index
evaluate one hour after intervention
Lactate
evaluate one hour after intervention
Eligibility criteria
Inclusion Criteria: 1. Patients aged 3 months to 18 years with critical condition 2. Suspected or confirmed infection, indicated by fever accompanied by signs of shock: 1. Mean arterial pressure 5th percentile, or 2. Systolic pressure ≤ 5th percentile, or 3. Diastolic pressure ≤ 5th percentile, or 4. Wide pulse pressure (diastolic pressure \< half of systolic pressure), or 5. Tachycardia accompanied by one or more of the following signs: Altered mental status, capillary refill time \> 2 seconds, temperature difference between extremities and core body, weaker peripheral arterial pulsation compared to the central pulsation, bounding pulse, mottled skin. Exclusion Criteria: 1. Contraindication of fluid loading (signs of fluid overload) 2. Burn injury, massive bleeding, dengue hemorrhagic fever. 3. Cardiogenic shock. 4. Deep anesthesia.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE2', 'PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'interventionModelDescription': 'Interventional subject will be received fluid loading with early norepinephrine administration with dose 0.1 mcg/kgBW/minute control subject will be received fluid loading only', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE', 'maskingDescription': 'fluid loading with norepinephrie'}}, 'enrollmentInfo': {'count': 42, 'type': 'ACTUAL'}}
Updated at
2024-06-17

1 organization